Savaysa

Chemical Nameedoxaban
Dosage FormTablet (oral; 15 mg, 30 mg, 60 mg)
Drug ClassInhibitors
SystemBlood
CompanyDaiichi Sankyo
Approval Year2015

Indication

  • To reduce the risk of stroke and systemic embolism (SE) in patients with nonvalvular atrial fibrillation (NVAF).
  • For the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) following 5 to 10 days of initial therapy with a parenteral anticoagulant.
Last updated on 8/29/2022

More on this drug: Clinical Trials

Document TitleYearSource
Savaysa (edoxaban) Prescribing Information.2021Daiichi Sankyo, Inc., Basking Ridge, NJ
Document TitleYearSource
Risk of stroke and bleeding in relation to hypertension in anticoagulated patients with atrial fibrillation: a meta-analysis of randomised controlled trials.2022Acta Cardiologica
A network meta-analysis of direct factor Xa inhibitors for the treatment of cancer-associated venous thromboembolism.2022Vascular
The use of non-vitamin K oral anticoagulants in dialysis patients—A systematic review.2022Seminars in Dialysis
The association of fracture risk in atrial fibrillation patients and longterm anticoagulant therapy category: a systematic review and meta-analysis. 2021PeerJ
Risk of intracranial hemorrhage with direct oral anticoagulants: a systematic review and meta analysis of randomized controlled trials. 2021Journal of Neurology
Warfarin versus DOACs in the prevention of thromboembolic stroke in patients with Afib. 2021Lynchburg Journal of Medical Science
Major gastrointestinal bleeding risk with direct oral anticoagulants: Does type and dose matter? A systematic review and network meta-analysis. 2021European Journal of Gastroenterology & Hepatology
Ranking the efficacy of anticoagulants for the prevention of venous thromboembolism after total hip or knee arthroplasty: a systematic review and a network meta-analysis. 2021Pharmacological Research
Oral anticoagulant agents in patients with atrial fibrillation and CKD: a systematic review and pairwise network meta-analysis. 2021American Journal of Kidney Diseases
The risk of gastrointestinal bleeding between non-vitamin K antagonist oral anticoagulants and vitamin K antagonists in the Asian atrial fibrillation patients: a meta-analysis. 2021International Journal of Environmental Research and Public Health
The risk of gastrointestinal hemorrhage with non-vitamin K antagonist oral anticoagulants: a network meta-analysis. 2021Medicine
A network meta-analysis comparing osteoporotic fracture among different direct oral anticoagulants and vitamin K antagonists in patients with atrial fibrillation. 2021Journal of Bone Metabolism
Pharmacogenetics of direct oral anticoagulants: a systematic review. 2021Journal of Personalized Medicine
Is chemoprophylaxis required after total knee and total hip arthroplasty in the Asian population? A systematic review and network meta-analysis.2021Thrombosis Research
Safety and efficacy of non-vitamin K antagonist oral anticoagulants in elderly patients with atrial fibrillation: systematic review and meta-analysis of 22 studies and 440 281 patients. 2021Cardiovascular Pharmacotherapy
Risk of stroke and bleeding in relation to hypertension in anticoagulated patients with atrial fibrillation: a meta-analysis of randomised controlled trials. 2021Acta Cardiologica
Efficacy and safety of anticoagulants for postoperative thrombophylaxis in total hip and knee arthroplasty: a PRISMA-compliant Bayesian network meta-analysis. 2021PLoS One
The efficacy and safety of edoxaban versus warfarin in preventing clinical events in atrial fibrillation: a systematic review and meta-analysis.2021The Anatolian Journal of Cardiology
Oral anticoagulant agents in patients with atrial fibrillation and CKD: a systematic review and pairwise network meta-analysis.2021American Journal of Kidney Disease
Economic evaluation of direct oral anticoagulants (DOACs) versus vitamin K antagonists (VKAs) for stroke prevention in patients with atrial fibrillation: a systematic review and meta-analysis.2021BMJ Evidence-Based Medicine
A network meta-analysis of non-vitamin K antagonist oral anticoagulants versus warfarin in patients with atrial fibrillation and diabetes mellitus.2021Acta Cardiologica
Comparative efficacy and safety of warfarin care bundles and novel oral anticoagulants in patients with atrial fibrillation: a systematic review and network meta-analysis.2020Scientific Reports
Non-vitamin K antagonist oral anticoagulants in elderly patients with atrial fibrillation: a systematic review with meta-analysis and trial sequential analysis. 2019Archives of Gerontology and Geriatrics
Interventions for preventing thromboembolic events in patients with atrial fibrillation: a systematic review.2018Annals of Internal Medicine
Stroke prevention in patients with atrial fibrillation: a systematic review update.2018Agency for Healthcare Research and Quality
Factor Xa inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in patients with atrial fibrillation.2018Cochrane Database of Systematic Reviews
Direct oral anticoagulants versus warfarin for preventing stroke and systemic embolic events among atrial fibrillation patients with chronic kidney disease.2017Cochrane Database of Systematic Reviews

Have we missed a study, or would you like to comment on a study?